CEACAM5 and colorectal cancer: To determine if immune responses and clinical benefit would be enhanced in patients with less tumor burden, we performed this pilot study to assess the immunogenicity and estimate clinical results of VRP-CEA vaccination in patients with stage III colorectal cancer.